PPARA and gastric cancer: Chen L et al. (2020) demonstrated that fenofibrate could induce mitochondrial reprogramming through activation of the AMPK pathway and inhibition of the HK2 pathway, inhibiting gastric cancer cell proliferation and promoting apoptotic through the PPARα pathway. Therefore, targeting PPARα may be an effective cancer treatment and has been tested in clinical trials. When “fenofibrate/bezafibrate | cancer” are taken as the search term, 18 clinical trials have been found on ClinicalTrial.gov, including a phase I study, 6 phase II studies, 5 phase III studies from 2006 to 2023 (Table 3).